Healthcare ❯Pharmaceuticals

Clinical Trials

Drug Development Weight Loss Drugs Cancer Treatment Mental Health HIV Prevention GLP-1s Competition Phase 3 Ketamine Weight-Loss Drugs Drug Safety Oncology Treatments Efficacy Studies PrEP Mpox Treatment Puberty Blockers Depression Treatments Multiple Myeloma Diabetes Treatment Neurological Conditions Drug Approval Drug Supply New Chemical Entities ALS Regulatory Approval Weight Loss Treatments Phase 2 Weight Management Response Rate Drug Effectiveness Phase 3 Trials Semaglutide Candidates

SPARC Shares Plunge Nearly 20% After Failed Phase 2 Vibozilimod Trials

Halting atopic dermatitis trials, Sun Pharma is collaborating with SPARC on new development plans following Vibozilimod’s failure to meet primary endpoints.

Sun Pharma Shares Drop 5% Following Mixed Q4 FY25 Results

Bristol Myers Squibb to Acquire 2seventy Bio in $286 Million Deal

Pfizer Faces Activist Pressure as Ex-Execs Withdraw Support for Starboard

Lenacapavir Injection Shows 96% Efficacy in Preventing HIV

New Studies Confirm Safety of Semaglutide for Mental Health

New Non-Hormonal Drug Shows Promise for Menopausal Hot Flashes

Roche's New Weight Loss Pill Shakes Up Pharmaceutical Market

Ketamine Shows Promise for Treatment-Resistant Depression in Clinical Trials

Alnylam's Heart Drug Shows Promising Phase-3 Results, Boosting Stock

Zealand Pharma's Petrelintide Shows Promising Results in Early Weight Loss Trial

Gilead's Lenacapavir Shows 100% Efficacy in HIV Prevention Trial

China's Weight-Loss Drug Market Faces Surge in Demand and Rising Competition

Wegovy Shows Promising Results in Heart Failure and Diabetes Treatment

Viking Therapeutics' Weight Loss Drug Shows Promise in Early Trial

Wegovy Approved for Heart Health, Faces Insurance Coverage Challenges

ALS Drug Relyvrio Fails Key Clinical Trial, May Be Pulled from Market